AnalystsSerge BelangerSerge Belanger's Stock Forecasts
AnalystsSerge Belanger
Analyst Ranking
Top 6%
#237 out of 4559 analysts
Average Return
+8.98%
Win Rate
47%99 out of 211
Risk vs Reward
Poor
Good
Serge Belanger's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Arcutis Biotherapeutics IncARQT | +282.05% | $2.34 | $8.94 | 2023-11-05 - 2024-04-22 | Buy |
Arcutis Biotherapeutics IncARQT | +282.05% | $2.34 | $8.94 | 2023-11-05 - 2024-04-22 | Buy |
Heron Therapeutics IncHRTX | +201.16% | $0.86 | $2.59 | 2023-11-14 - 2024-04-22 | Buy |
Liquidia CorpLQDA | +176.08% | $2.55 | $7.04 | 2021-03-22 - 2022-03-22 | Buy |
Verrica Pharmaceuticals IncVRCA | +120.81% | $3.08 | $6.79 | 2023-11-09 - 2024-04-22 | Buy |
Serge Belanger Analyst Color
Get additional color on Serge Belanger's coverage of popular stocks
Serge Belanger's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Xenon Pharmaceuticals IncXENE | 8 | Buy | $62.00 | +54.96% | Reiterates | 11 days ago |
Arcutis Biotherapeutics IncARQT | 11 | Buy | $16.00 | +78.97% | Reiterates | 11 days ago |
Kalvista Pharmaceuticals IncKALV | 10 | Buy | $35.00 | +205.94% | Reiterates | 12 days ago |
Heron Therapeutics IncHRTX | 12 | Buy | $5.00 | +93.05% | Reiterates | 12 days ago |
Collegium Pharmaceutical IncCOLL | 19 | Buy | $40.00 | +15.14% | Reiterates | 12 days ago |
Biocryst Pharmaceuticals IncBCRX | 7 | Buy | $12.00 | +172.11% | Reiterates | 13 days ago |
Liquidia CorpLQDA | 17 | Buy | $28.00 | +112.44% | Reiterates | 13 days ago |
Esperion Therapeutics IncESPR | 13 | Buy | $8.00 | +318.85% | Reiterates | 13 days ago |
Evolus IncEOLS | 8 | Buy | $22.00 | +87.71% | Reiterates | 13 days ago |
Pacira Biosciences IncPCRX | 17 | Buy | $45.00 | +72.41% | Reiterates | 14 days ago |
Cormedix IncCRMD | 10 | Buy | $10.00 | +89.39% | Reiterates | 14 days ago |
Trevi Therapeutics IncTRVI | 10 | Buy | $8.00 | +172.11% | Reiterates | 14 days ago |
Moonlake ImmunotherapeuticsMLTX | 6 | Buy | $66.00 | +60.90% | Reiterates | 14 days ago |
Cytokinetics IncCYTK | 11 | Buy | $108.00 | +62.92% | Reiterates | 14 days ago |
Viridian Therapeutics IncVRDN | 7 | Buy | $30.00 | +109.79% | Maintains | a month ago |
Clearside Biomedical IncCLSD | 6 | Buy | $4.00 | +183.69% | Reiterates | a month ago |
Verrica Pharmaceuticals IncVRCA | 10 | Buy | $8.00 | +17.82% | Reiterates | 2 months ago |
Revance Therapeutics IncRVNC | 14 | Buy | $18.00 | +394.51% | Maintains | 2 months ago |
Dice Therapeutics IncDICE | 1 | Buy | $56.00 | N/A | Reiterates | a year ago |
Tricida IncTCDAQ | 2 | Hold | N/A | N/A | Downgrades | a year ago |
Phasebio Pharmaceuticals IncPHASQ | 3 | Hold | N/A | N/A | Downgrades | 2 years ago |
Aerie Pharmaceuticals IncAERI | 5 | Hold | N/A | N/A | Downgrades | 2 years ago |
Clarus Therapeutics Holdings IncCRXTQ | 4 | Hold | N/A | N/A | Downgrades | 2 years ago |
Akebia Therapeutics IncAKBA | 1 | Hold | N/A | N/A | Downgrades | 2 years ago |
Zogenix IncZGNX | 3 | Hold | N/A | N/A | Downgrades | 2 years ago |
Flexion Therapeutics IncFLXN | 1 | Buy | $18.00 | N/A | Maintains | 3 years ago |
Calcimedica IncCALC | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Gw Pharmaceuticals PLCGWPH | 3 | Hold | N/A | N/A | Downgrades | 3 years ago |
Zynerba Pharmaceuticals IncZYNE | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.